IGF1 and myeloproliferative disorder: The identification of this optimal IGF1 range provides a concrete therapeutic target for interventions; however, the clinical utility and cost effectiveness of serial IGF1 measurements in this specific patient population require further investigation to determine whether achieving and maintaining IGF1 levels within the 120–160 ng/mL range translates into improved quality-of-life outcomes and survival benefits in myeloproliferative neoplasm patients.